NGNE Company Profile and Key Details

NGNE has shown mixed momentum, gaining 1.39% over the past week and -39.65% over the past quarter, though year-to-date performance is down -14.95%. Short-term trend indicators are bullishly aligned (SMA20 10.22%, SMA50 5.54%, SMA200 -6.18%). The stock’s 14-day RSI is 57.9 (neutral), while the ATR of 1.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -47.19% below its high and over 186.25% above its low. Average 10-day trading volume of 385.98 thousand shares is significantly above the 3-month average of 255.59 thousand, indicating heightened recent market interest.

Neurogene Inc. has 20.01 million shares outstanding. The public float is 11.33 million shares, elevated short interest at 17.88% of float. This equals 3.01 million shares. The short ratio is 10.93 days. Institutional investors hold 95.23% of the float. Insiders own 7.07%. Samsara BioCapital GP, LLC holds 1.69 million shares, McMinn Rachel has 1.34 million shares and Cvijic Christine Mikail has 84.04 thousand shares. Over the past six months, insider transactions show net selling. They sold 18.61 thousand shares across 8 transactions.

Neurogene Inc. generated EPS of -$4.43 over the past year. Five-year average earnings growth is -10.74%. Wall Street analysts project EPS growth of -9.11% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $200.00 to $45.00. The high target offers 523.25% upside. The low target suggests 40.23% downside. The mean target is $93.75. This offers 192.15% upside. Neurogene Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 7.75%. The prior quarter beat by 7.23%. Over the last six quarters, Apple has recorded several small beats. These include -8.7% in August 11, 2025.

Neurogene Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.44. This means the shares are trading above this model’s fair value.

Neurogene Inc. (NASDAQ:NGNE) closed at $32.09 USD, losing -$0.32 (-0.99%) from the previous close of $32.41. The stock is currently mid-range between its 52-week high and low $15.93 and $43.66. With a market capitalization of about $507.10 million, Neurogene Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.96). Key stats such as the average daily volume over the past year has been around 255.71 thousand shares, trading with heavier-than-usual volume. Headquartered in New York City, NY, Neurogene Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rachel L. McMinn, the company employs approximately 131 people and listed since March 07, 2014. Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions.

Neurogene Inc. trades at a P/E ratio of -5.82, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.33 trading at moderately above to book value. The P/FCF stands at -5.82, also below market averages.

Our AI price prediction model suggests that Neurogene Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.7%, with price expected at $29.62 by October 02, 2026, within a range of $28.35 to $30.94 3-Month Outlook: Projected rise of 102.21%, reaching $64.89 by December 17, 2026, with a range of $63.37 to $66.94. 1-Year Outlook: Projected gain of 8.88%, with price at $34.94 by September 17, 2027, within a range of $29.80 to $38.38.

Neurogene Inc. (NASDAQ:NGNE) shares are down -14.95% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Neurogene Inc. trading at a premium to the broader market with a P/E of -5.82. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $73.59, suggesting 129.32% upside. Our AI forecast model points to short-term weakness (-7.7% over two weeks), a medium-term rise (102.21% over three months), and a longer-term gain (8.88% over one year), with expected trading ranges indicating moderate volatility.